RANEXA 375 price in UAE

Overview

Welcome to Dwaey, specifically on RANEXA 375 Tablets/Prolonged Release page.
This medicine contains an important and useful components, as it consists of Ranolazine.
RANEXA 375 is available in the market in concentration 375mg/Tablet and in the form of Tablets/Prolonged Release.

MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA is the producer of RANEXA 375 and it is imported from LUXEMBOURG, The most popular alternatives of RANEXA 375 are listed downward .

Mode Of Action

Ranolazine exert its antianginal and anti-ischaemic effects through concentration-, voltage-, and frequency-dependent inhibition of the late Na current and other cardiac ion channels and transporters. It may decrease the magnitude of the late Na current resulting in a net reduction in intracellular Na concentrations, reversal of Ca overload, restoration of ventricular pump function, and prevention of ischaemia-induced arrhythmias. Its antianginal effects are not dependent upon reductions in heart rate or BP and QT interval prolongation effect is caused by inhibition of rapid delayed rectifier K current (IKr), which prolongs the ventricular action potential.

Indication

Chronic angina

Precaution

Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems. Lactation: Unknown if excreted in breast milk; discontinue or do not nurse

Side Effects

>10% Dizziness (5-13%) 1-10% Nausea (4-9%)
Constipation (5-8%)
Headache (3-6%)
Syncope (3%) Frequency Not Defined Palpitations
Bradycardia
Peripheral edema
Prolonged QT interval
Abdominal pain
Dry mouth
Dyspepsia
Anorexia
Vomiting
Hematuria
Dyspnea
Tinnitus
Vertigo
Blurred vision
Vasovagal syncope
Confusional state
Hematuria
Hyperhidrosis

Contra indication

Taking strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin, nelfinavir) Taking inducers of CYP3A (e.g., phenobarbital, rifampicin)Significant hepatic impairment

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine). Potentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.